A new drug has been found to slow cognitive and functional decline in people with early symptomatic Alzheimer’s disease (AD), according to the results of the phase 3 clinical trials.
The data about the drug donanemab, developed by American pharmaceutical firm Eli Lilly and Company, was shared at the 2023 Alzheimer’s Association International Conference (AAIC) in the Netherlands, and simultaneously published in the Journal of the American Medical Association (JAMA).
“The positive data bring hope to people with Alzheimer’s disease who urgently need new treatment options,” said Anne White, executive vice president of Eli Lilly and Company.
Bhupendra Singh Chundawat is a seasoned technology journalist with over 22 years of experience in the media industry. He specializes in covering the global technology landscape, with a deep focus on manufacturing trends and the geopolitical impact on tech companies. Currently serving as the Editor at Udaipur Kiran, his insights are shaped by decades of hands-on reporting and editorial leadership in the fast-evolving world of technology.